Among the most neglected tropical diseases in the world, one is leishmaniasis, which is caused by parasites that belongs to protozoans of the genus Leishmania. Leishmaniasis can be controlled profoundly by using chemotherapeutic agents which includes pentavalent antimonials, paromomycin, pentamidine, amphotericin B and miltefosine, as it depends greatly on it. The only oral drug used with high cure rate is miltefosine used for the treatment of visceral leishmaniasis but its observed susceptibility decrease in countries like India where it is extensively used. Hence, the development of novel antileishmanial agents with good potency and better therapeutic profile is very necessary. Here we review diverse classes of secondary metabolites, focusing on antiparasitic compounds, biosynthesized by fungi. Fatima et al.; BJPR, 12(2): 1-12, 2016; Article no.BJPR.26094 2
INTRODUCTION
One of the most important parasitic diseases of humans is leishmaniasis, causing significant morbidity and mortality according to the World Health Organization. Species of the genus Leishmania (Trypanosomatidae) were first described separately in 1903 by Leishman and Donovan in patients from India. Millions of people are still affected by Leishmania and about 2 million new cases appeared annually. Moreover, about 350 million people live at risk of infection with Leishmania parasites. The incidence of leishmaniasis is increasing due to projects that are made by man and that have a great impact on environmental, including deforestation, irrigation systems and wells, as well as dams that increase human exposure to the sandfly vector. The risk of Leishmania-infected people to develop potentially fatal visceral leishmaniasis increases in people with suppressive immune system such as acquired immunodeficiency syndrome (AIDS) [1] . Natural products from plants have proven to be a valuable source of chemical matter for anti-infective programs. In natural products fungal metabolites play an important role in drug discovery and drug development and they provide lead compounds.
ETIOLOGY
There are 17 different species of protozoan parasites belonging to the genus Leishmania that cause leishmaniasis. The parasite of Leishmania is present in two forms amastigote and promastigote. Amastigote stage is nonflagellated and ovoid shape of leishmania [2] . Central round or oval nucleus and adjacent but smaller round or rod shaped kinetoplast can be observed through simple light microscopy. The promastigote form of parasite is found in sandfly host. Its transformation from amastigotes mostly occurs in gut and starts within hours of ingestion of the amastigotes. The complete motile promastigotes are formed within 24-48 h with continue binary division that leads to development of disease [3, 4] .
MODES OF TRANSMISSION
For implementation of an effective intervention strategy, it is important to study complete transmission mechanism of any infectious agent. Pathogens have to be transferred from a source to a susceptible host to cause an infection. The modes of transmission of infection are;
Vector-borne Transmission
The most common mode of transmission is vector-brone transmission worldwide [5] . Leishmania amastigotes are swallowed and circulates freely in the body, after the bite of sandfly to the infected host. Stationary, infectivestage organisms that could be qualified as "metacyclic" promastigotes are formed by the amastigote migration to sand flies proboscis. Upon the bite of infected sandfly to a second host, e.g., a human being, these promastigotes are released on the site of bite or injected and deposited over there, long-lasting erythema is produce by potent vasodilators (i.e., maxadilan) that was deposited along the promastigote [6,7].
Congenital Transmission
In 1962 the 1 st case of congenital leishmaniasis was reported by Low & Cooke [8] . Leishmania donovani passed through the placenta of the Syrian hamster and mice but in aborted 5 months fetus, no parasite could be demonstrated in the organs while numerous amastigotes were found in the placenta [9] . This infection might have occurred in most of these cases during the exchange of mother's blood at the time of passage of fetus through birth canal. The infection of congenital visceral leishmaniasis may change to Leishmania acquired through sandfly bite within three months of life [9, 10] . The susceptibility to leishmaniasis is high in pregnant women due to shift of cell mediated immunity to humoral immunity [11].
Sexual Transmission
Promastigotes were found in cultures of urine and prostatic fluid from patients with visceral leishmaniasis. Transmission via a sexual route is common; include transmission from a man to his wife and in homosexual man suffering from AIDS [12] .
Occupational (Needle Stick) Exposures
Number of cases of AIDS and about 200 cases of HIV-associated leishmaniasis were detected earlier in Spain, in which more than 85 per cent occurred among intravenous drug users (IVDUs). The infection with amastigote is so common in 17% of 111 bone marrow aspirates with HIV positive subject. Alvar et al. [1] described L. infantum zymodemes, in blood of the persons who are drug user and share syringes and, therefore, they act as a carrier. In another study, Molina et al. [13] tested the indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients, of whom nine were IVDUs thereby indicating the possibility of needlemediated transmission [13, 14] .
CLINICALLY DIFFERENT FORMS OF LEISHMANIASIS
There are three clinically distinguishable forms of leishmaniasis: cutaneous, mucocutaneous, and visceral.
Cutaneous Leishmaniasis
Skin is involved in it and exposed parts of the body such as the face, arms and legs may get skin ulcer due to cutaneous leishmaniasis. A large number of lesions ranging from one to dozens are produced. According to the infecting Leishmania species, the lesions may appear as smooth nodules, ulcers, flat plaques or hyperkeratotic wart-like lesions.
Immunosuppressive conditions like infection with the human immunodeficiency virus (HIV) or the steroid treatment can result in unusually severe cutaneous leishmaniasis [15] .
Mucocutaneous Leishmaniasis
Mucocutaneous leishmaniasis is a rare form of the disease usually occurs in Latin America. It tends to occur months or years after the healing of a cutaneous leishmaniasis ulcer, but it can also appear during the skin ulcers. Ulcerations and erythema at the nose are the first signs, which may develop into a destructive inflammation to involve the nasal septum, the pharynx or larynx. Mucocutaneous leishmaniasis does not heal spontaneously, and the destructive inflammation may cause severe disfigurement of face due to the nasal septum perforate, or pharynx or larynx blockade [16] .
Visceral Leishmaniasis
The most common symptoms of visceral leishmaniasis, are an intermittent fever, decreased appetite, abnormal weight loss, anemia, and abdominal distension with enlargement of the liver and spleen. The sensitivity to infections with other microorganisms increases with thrombocytopenia, a low platelet count, result in abnormal bleeding, including hemorrhages or mucous membranes petechiae, and leukopenia. This form of the disease is always fatal, due to other infections and complications, as no treatment was provided. In patients co-infected with HIV, this disease is very fatal [17] .
ANTILEISHMANIAL DRUGS AND PRESENT STATUS
Amphotericin B (1) is a polyene antibiotic with selective and high affinity for ergosterol a major sterol in fungi and Leishmania parasites. Therefore this antibiotic is considered selective drug against these organisms [18] [19] [20] . The sensitivity of different species (having differences in the type and quantity of sterols in the membranes) of Leishmania to amphotericin B is not compared. Amphotericin B leads to accumulation of 14-α-methyl sterols by inhibiting 14-α-demethylation of lanosterol which is mediated by cytochrome 450 enzymes. The accumulation of 14-α-methyl sterols cause blockage of synthesis of ergosterol in Leishmania parasites [21-23].
Pentavalent Antimonials (Pentostam and Glucantime)
More than half of a century, pentavalent antimonials (antimony compounds) including sodium stibogluconate (Pentostam) (2) and meglumine antimoniate (Glucantime) (3), have been used for treatment of leishmaniasis. Despite of several side effects such as need for daily parenteral administration and drug resistance, they are still considered as 1 st line therapy. The antimonial's mechanism of action, molecular structure and metabolism are still under investigation. The final active form whether is sodium stibogluconate Sb(V) or Sb(III), is still unclear. Studies showed that the mechanism of action of pentavalent antimonials can be proposed by three different models [24] . Prodrug model; According to this model, pentavalent antimony Sb(V) behaves as a prodrug, which undergoes biological reduction to much more active/toxic trivalent form of antimony Sb 
Pentamidine
Pentamidine (pentamidine mesylate) (4) is an antiparasitic and apoptotic drug used for treatment of leishmaniasis [23,27].
Miltefosine
Miltefosine (5) is an alkylphosphocholine which acts by interfering cell signal-transduction pathways and inhibits phospholipids and sterol biosynthesis and has a major role in cancer treatment. It inhibits ornithine decarboxylase and polyamine biosynthesis irreversibly. It has also been developed for treatment of leishmaniasis. It is effective against both the stages of leishmanial parasites i.e. promastigotes and amastigotes and is used orally [28, 29] . Natural products are considered an important domain for antileishmanial drug discovery. 
NATURAL PRODUCTS AND LEISHMANIASIS
Despite of the continuous efforts in drug discovery and drug development against leishmaniasis current therapies are not much effective and there is a need for discovery of more effective antileishmanial agents [46] .
In view of the present scenario, development and introduction of new antileishmanial compounds would be an urgent need due to the toxicity of the clinically used drugs and the continuous sideeffects even after adjustment of dose and duration of treatment.
In the ongoing search for new drugs, natural products are gaining ground being easily available and relatively cheap. Furthermore, valuable synthetic compounds can be obtained from the leads with antileishmanial activity obtained from natural sources (plants and microorganisms). Thus, in the present study we have reviewed antileishmanial compounds from fungi which is less explored site. In another study, it is reported that perylene quinonoids, hypocrellin A and B (7, 8) isolated from fungus Hypocrella bambusae. Hypocrellin A showed significant antileishmanial activity against L. donovani (IC 50 0.27±0.03 µg/ml), while B was moderately active with IC 50 12.7± 3.1 µg/ml) [52] . In 2005 Marinho and his collegues studied antileishmanial potential of methanolic extract of an endophytic fungus Penicillium janthinellum isolated from the fruit of Brazilian plant Melia azedarach (Meliaceae). They isolated a known polyketide metabolite citrinin (9) which showed 100% inhibition of L. mexicana at 40 µg/ml [53] . A biphenyl derivative, altenusin (10) isolated from Alternaria sp., showed inhibitory activity against L. amazonensis [54] . Crude ethyl acetate extract from phaseolorum sp., Phyllosticta sp., Phomopsis sp. and Cercospora kikuchii showed inhibition of growth of L. tarentolae [55] . Another fungus Cochliobolus sp., isolated from Piptadenia adiantoides was also studied for antileishmanial effects. Alcoholic extract showed significant results and two compounds cochlioquinone A and isocochlioquinone A were purified by its further fractionation (11,12). Both compounds showed antileishmanial activity against L. amazonensis, with EC 50 values of 1.7 µM and 4.1 µM, respectively [56] . Phytochemical investigation of the fungus Chaetomium sp., leads to isolation of three new xanthone compounds. These chaetoxanthones A−C (13-15) exhibited significant activities against L. donovani with IC 50 values of 5.3, 3.4, and 3.1 µg/ml, respectively [57] .
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Fig. 2. Antileishmanial compounds from fungi (6-15)
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CONCLUSION
Leishmaniasis mostly affects people of developing countries living below poverty line and is a life threatening disease. The main cause of leishmaniasis pathogenesis and manifestations is poor sensitizations, malnutrition and unhealthy living environment factors. Increased resistance to the available drug regimen urges the need for the development of new cost effective drugs. This review signified the antileishmanial potential of fungal metabolites for further drug development.
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